Adding the IV drug to loop diuretics in the ADVOR trial improved decongestion success in volume-overloaded patients with acute decompensated heart failure, researchers reported.
In the ADVOR trial, the addition of IV acetazolamide to standard IV loop diuretics improved acute congestion at 3 days in nearly 50% more patients vs. placebo in the setting of acute decompensated HF and volume overload.“ADVOR is the first trial ever in acute heart failure to show a positive result with regards to very clinically important and relevant endpoints,” Wilfried Mullens,
Study met all primary safety and efficacy endpoints for the Cordella PA Pressure Sensor System for the treatment of NYHA class III heart failure patients LISLE, Ill., May 23, 2022